Monitor upcoming Phase 1 data readout for HCW9302 in mid-2026 and Nasdaq appeal outcome for bid price deficiency. The $3.5M licensing cash could extend runway but going concern doubts persist.
Price Chart
Executive Summary
HCW Biologics reported a net loss of $3.4M for Q4 2025, missing EPS estimates by 625% due to a $1.5M impairment charge. The company received a $3.5M upfront license fee from Trimmune and regained Nasdaq compliance, but faces going concern doubts and a bid price deficiency.
Key Financial Metrics
Key Facts
- Received $3.5M upfront license fee from Trimmune for HCW11-006
- Regained Nasdaq compliance but now faces bid price deficiency
- Substantial doubt about going concern remains
- Initiated Phase 1 trial for HCW9302 in alopecia areata
- Published CAR-T manufacturing data in Science Advances
Financial Impact
Net loss of $3.4M (including $1.5M impairment) vs. consensus EPS miss of $1.80
Risk Factors
- Substantial doubt about going concern for next 12 months
- Nasdaq bid price deficiency with no cure period due to prior reverse split
- High R&D spend ($5.4M annually) with no near-term revenue visibility
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-134936 |
| Document: hcwb-20260331.htm | 0001193125-26-134936 |
| Document: 0001193125-26-134936-index-headers.html | 0001193125-26-134936 |
| Document: 0001193125-26-134936-index.html | 0001193125-26-134936 |
| Document: 0001193125-26-134936.txt | 0001193125-26-134936 |
| 8-K Data (Synthetic) | 0001193125-26-134936 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 14d ago | EFFECT | $1.26 | awaiting T+60 | — | $1.10 (+12.70%) |
Oct 2, 2026 24d ago | S-1 | $1.64 | awaiting T+60 | — | $1.10 (+32.93%) |
Oct 1, 2026 26d ago | DEF 14A | $1.69 | awaiting T+60 | — | $1.10 (+34.91%) |
Sep 24, 2026 4w ago | 8-K | $1.99 | awaiting T+60 | — | $1.10 (+44.72%) |
Aug 20, 2026 9w ago | S-1 | $2.12 | awaiting T+60 | — | $1.10 (−48.11%) |
Aug 14, 2026 10w ago | 8-K | $2.68 | awaiting T+60 | — | $1.10 (+58.96%) |
Aug 14, 2026 10w ago | Press Release | $2.68 | awaiting T+60 | — | $1.10 (+58.96%) |
Aug 14, 2026 10w ago | 10-Q/A | $2.68 | awaiting T+60 | — | $1.10 (+58.96%) |
Aug 14, 2026 10w ago | 8-K | $2.68 | awaiting T+60 | — | $1.10 (+58.96%) |
Jul 29, 2026 12w ago | Press Release | $2.58 $1.12 | ▲ +56.59% | ▲ +61.32% | $1.10 (+57.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers